Statements (81)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Company
|
| gptkbp:acquired |
GSK's vaccine business in China
|
| gptkbp:acquisition |
various pharmaceutical companies
|
| gptkbp:ceo |
Liang Zhiqiang
|
| gptkbp:collaborates_with |
gptkb:WHO
various universities |
| gptkbp:employees |
over 50,000
|
| gptkbp:focus |
healthcare solutions
|
| gptkbp:focus_area |
gptkb:biotechnology
gptkb:health_services gptkb:supply_chain_management patient education telemedicine chronic disease management clinical trials public health initiatives generic drugs medical education medical logistics clinical research community health programs healthcare workforce planning healthcare quality improvement public health research healthcare analytics healthcare policy development pharmaceutical manufacturing pharmaceutical research patient safety initiatives healthcare consulting vaccine development patient care services pharmacovigilance drug safety healthcare IT solutions digital health solutions healthcare technology integration medical research funding healthcare access initiatives healthcare workforce development healthcare policy advocacy medical device innovation regulatory affairs medical ethics training pharmaceutical marketing medical research ethics healthcare data management healthcare research collaboration pharmaceutical regulatory compliance healthcare system strengthening pharmaceutical education programs healthcare system evaluation innovative drugs pharmaceutical retail pharmaceutical supply chain management pharmaceutical pricing strategies medical technology assessment healthcare financing solutions healthcare infrastructure development healthcare innovation hubs healthcare service delivery models pharmaceutical market access strategies pharmaceutical supply chain optimization |
| gptkbp:founded |
gptkb:2003
|
| gptkbp:headquarters |
gptkb:Beijing,_China
|
| https://www.w3.org/2000/01/rdf-schema#label |
Sinopharm Group Investment
|
| gptkbp:industry |
gptkb:pharmaceuticals
|
| gptkbp:market_cap |
publicly traded
|
| gptkbp:operates_in |
gptkb:China
|
| gptkbp:parent_company |
gptkb:China_National_Pharmaceutical_Group
|
| gptkbp:partnerships |
international pharmaceutical firms
|
| gptkbp:products |
gptkb:medical_devices
vaccines diagnostic products |
| gptkbp:revenue |
over 100 billion CNY
|
| gptkbp:services |
pharmaceutical distribution
|
| gptkbp:stock_symbol |
601607. SS
|
| gptkbp:subsidiaries |
gptkb:Sinopharm_Holding
|
| gptkbp:website |
www.sinopharm.com
|
| gptkbp:bfsParent |
gptkb:China_National_Pharmaceutical_Group_Corporation
|
| gptkbp:bfsLayer |
5
|